Slide 1: Aroa Biosurgery Quarterly Report
For personal use only Aroa Biosurgery (ARX) | Quarterly Report UNLOCKING REGENERATIVE HEALING FOR EVERYBODY
Slide 2: Important Notice and Disclaimer
Important Notice and Disclaimer For personal use only This presentation (Presentation) is dated 29 January 2025 and has been prepared by Aroa solely on their own judgement, review and analysis when making an investment decision Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (AR
Slide 3: Unlocking Regenerative Healing for Everybody
Unlocking For personal use only Regenerative healing for everybody. World-leading outcomes Unmatched value Widespread impact
Slide 4: AROA at a Glance
AROA at a Glance Well established high-growth soft tissue regeneration company For personal use only Four product AROA ECM platform families for new products, line >US$3B1 TAM predominantly sold to extensions & enables AROA’s for existing products US hospitals tissue apposition platform US Direct (A
Slide 5: AROA ECM – Structure & Biology for Regenerative Healing
AROA ECM – Structure & Biology for Regenerative Healing Unique Extracellular Matrix (ECM) derived from ovine forestomach with proven tissue regeneration properties across multiple products1-6 For personal use only Orchestrates Optimal Structure Angioconductive Functional & Biology Regeneration 1. Ir
Slide 6: Substantial Growth Opportunities > $3B TAM
Substantial Growth Opportunities > $3B1 TAM For personal use only Total Addressable Market Total Addressable Market > $1.8B USD 2 > $1.3B USD 3 e.g. Diabetic Foot Ulcers, Venous e.g. Trauma, tumour removal, general e.g. Hernia repair, abdominal Ulcers, Pressure Ulcers, chronic wounds surgery, inflam
Slide 7: Q2 FY25 Financial Highlights
Q2 FY25 Financial Highlights For personal use only Positive cash flows from operations of NZ$1.2 million. 01 The first quarter of positive cashflow since admission to the ASX in July 2020. Net cash outflow from investing activities was NZ$0.8 02 million, reflecting routine capex. 03 Strong cash rece
Slide 8: Q2 FY25 Operational Highlights
Q2 FY25 Operational Highlights For personal use only 46% YOY growth in Myriad sales, with AROA Direct sales now 01 making up 56% of overall sales mix. Largest prospective study of lower extremity reconstructions using a dermal substitute. Tissue fill and coverage achieved in 02 30 days with no infec
Slide 9: FY25 Guidance
FY25 Guidance For personal use only NZ$81-84m NZ$2-4m Total Revenue Normalised EBITDA (Constant Currency NZ$76 – 79m) (Constant Currency NZ$0 – 2m) 1. This guidance reflects an average NZ$/US$ exchange rate of 0.60 for FY25. 2. Normalised EBITDA is non-conforming financial information, as defined by
Slide 10: Myriad: Simplify surgical soft tissue reconstruction
Myriad Simplify surgical soft tissue reconstruction For personal use only 1 VASCULARIZED MINIMAL SINGLE TISSUE COVERAGE COMPLICATIONS APPLICATION WITHIN 4 WEEKS Low infection rate & zero graft A median of one 100% coverage and fill loss, even in contaminated product application1-3 in 23-30 days.1-3
Slide 11: How does Myriad Compare?
How does Myriad Compare? For personal use only Publications Number of Publications Reported Number of Published Reported Reference Product class Reporting Reported Reporting Graft Publications Patients Infection Range Infection Infections Graft Loss Loss Range Biologic – 1/279 Myriad 12 279 1 (8%) 0
Slide 12: Questions & Answers
For personal use only AROA BIOSURGERY Questions & Answers
Slide 13: 'Real World' Limb Salvage Study
‘Real World’ Limb Salvage Study Limb Salvage via Surgical Soft Tissue Reconstruction with Ovine Forestomach Matrix Graft: A prospective study For personal use only Brandon Bosque, DPM, CWSP Senior Medical Science Liaison, Aroa Biosurgery John C. Lawlor, DPM Podiatric Surgeon – Associates in Medicine
Slide 14: Summary
Summary For personal use only Myriad achieved 100% tissue coverage and fill in 30 01 days, with no infections or complications. 02 Median product application of one. Study findings demonstrate cost differences of up to 03 195% compared with other dermal matrices. Largest prospective inpatient study
Slide 15: Questions & Answers
For personal use only AROA BIOSURGERY Questions & Answers
Slide 16: Thank you for attending
Thank you For personal use only for attending JAMES AGNEW investor@aroa.com VISIT www.aroa.com www.linkedin.com/company /aroa-biosurgery-limited/ 64 Richard Pearse Drive, Auckland 2022, New Zealand PO Box 107111, Auckland Airport, Auckland 2150, New Zealand